Principal investigatorD. Logeart-Avramoglou

InvestigatorsM. Manassero

Another strategy to improve bone repair consists in recruiting local osteocompetent cells (in periphery of the bone defect) via the use of bioactive factors. In that perspective, BMPs (Bone Morphogenetic Protein) are of particular interest as they are osteinductive molecules (i.e. inducing bioactive cascades leading to new bone formation) with a specific action on bone and cartilage.

In clinical practice, BMP-2 is actually use for different medical applications where new bone formation is required. It is then added in absorbable collagen sponges which will deliver the BMP2 as they get degraded. Supra-physiological doses (in the tens of milligrams range) are, however, required for such applications because of the low affinity of BMP-2 for collagen, risking unwanted side effects and raising the cost of such therapeutic to levels prohibitive for a large scale clinical use.

The B3OA, therefore, aims to test new systems of controlled release of BMP in order to minimize the risk and the cost associated with this therapeutical strategy.

Publications of the project

Guillot R., Gilde F., Becquart P., Sailhan F., Lapeyrere A., Logeart-Avramoglou D., Picart C. The stability of BMP loaded polyelectrolyte multilayer coatings on titanium. Biomaterials 34(23):5737-46 (2013). Link for the publication .

Decambron A, Fournet A, Bensidhoum M, Manassero M, Sailhan F, Petite H, Logeart-Avramoglou D, Viateau V. Low-dose BMP-2 and MSC dual delivery onto coral scaffold for critical-size bone defect regeneration in sheep. J Orthop Res. 35 (12): 2637-2645 (2017). Link for the publication .

Decambron A, Devriendt N, Larochette N, Manassero M, Bourguignon M, El-Hafci H, Petite H, Viateau V, and Logeart-Avramoglou D. Effect of the BMP-2 doses on the osteogenic potential of hMSCs – containing tissue engineering constructs. Tissue Eng Part A. (2018). Link for the publication .